Author + information
- Received March 2, 2018
- Revision received May 1, 2018
- Accepted May 3, 2018
- Published online July 2, 2018.
- Joseph J. Maleszewski, MDa,b,∗ (, )
- Melanie C. Bois, MDa,
- John P. Bois, MDb,
- Philip M. Young, MDc,
- John M. Stulak, MDd and
- Kyle W. Klarich, MDa
- aDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- bDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
- cDepartment of Radiology, Mayo Clinic, Rochester, Minnesota
- dDepartment of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
- ↵∗Address for correspondence:
Dr. Joseph J. Maleszewski, Mayo Clinic, 200 First Street S.W., Rochester, Minnesota 55905.
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon. This recognition has led to the emergence of cardio-oncology as a true subspecialty. This field is not simply limited to primary cardiac tumors or complications of chemotherapeutic medications. Rather, it also encompasses metastatic cardiovascular complications and secondary cardiovascular effects of the underlying neoplasia. This review will broadly cover primary and metastatic cardiac neoplasms, as well as secondary cardiovascular effects of extracardiac neoplasia (e.g., amyloidosis, carcinoid valvulopathy, and chemotherapeutic cardiotoxicities).
Dr. Young has served as a consultant for Arterys. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received March 2, 2018.
- Revision received May 1, 2018.
- Accepted May 3, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.